Related references
Note: Only part of the references are listed.2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Jasvinder A. Singh et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges
Josef S. Smolen et al.
NATURE REVIEWS RHEUMATOLOGY (2015)
Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate Results of a Phase III Study
Mark C. Genovese et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Belimumab for Systemic Lupus Erythematosus: A Cochrane Systematic Review and MetaAnalysis
Jasvinder A. Singh et al.
ARTHRITIS & RHEUMATOLOGY (2015)
How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?
Roy Fleischmann et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial
Tom W. J. Huizinga et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study
Mark C. Genovese et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Interleukin 6 and Rheumatoid Arthritis
Yuji Yoshida et al.
BIOMED RESEARCH INTERNATIONAL (2014)
The Biology and Medical Implications of Interleukin-6
Toshio Tanaka et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement
Monika M. Schoels et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
Gerd R. Burmester et al.
LANCET (2013)
Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Multiple Courses of Rituximab Produce Sustained Clinical and Radiographic Efficacy and Safety in Patients with Rheumatoid Arthritis and an Inadequate Response to 1 or More Tumor Necrosis Factor Inhibitors: 5-Year Data from the REFLEX Study
Edward C. Keystone et al.
JOURNAL OF RHEUMATOLOGY (2012)
Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment
Paul Emery
RHEUMATOLOGY (2012)
Tocilizumab Inhibits Structural Joint Damage in Rheumatoid Arthritis Patients With Inadequate Responses to Methotrexate Results From the Double-Blind Treatment Phase of a Randomized Placebo-Controlled Trial of Tocilizumab Safety and Prevention of Structural Joint Damage at One Year
Joel M. Kremer et al.
ARTHRITIS AND RHEUMATISM (2011)
Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials
Laura Campbell et al.
RHEUMATOLOGY (2011)
Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide
J. R. Curtis et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
G. Jones et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Total cholesterol and LDL levels decrease before rheumatoid arthritis
Elena Myasoedova et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
2010 Rheumatoid Arthritis Classification Criteria An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative
Daniel Aletaha et al.
ARTHRITIS AND RHEUMATISM (2010)
The role of Interleukin 6 in the pathophysiology of rheumatoid arthritis
Srinivasan Srirangan et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2010)
Inhibition of Interleukin-6 Receptor Directly Blocks Osteoclast Formation In Vitro and In Vivo
Roland Axmann et al.
ARTHRITIS AND RHEUMATISM (2009)
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
P. Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Interleukin-6 Receptor Inhibition With Tocilizumab Reduces Disease Activity in Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Antirheumatic Drugs The Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy Study
Mark C. Genovese et al.
ARTHRITIS AND RHEUMATISM (2008)
Extra-articular manifestations and complications of rheumatoid arthritis
Adam Young et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2007)
Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis - Results from a large UK national cohort study
Kimme L. Hyrich et al.
ARTHRITIS AND RHEUMATISM (2007)
Interleukin-6 levels in synovial fluids of patients with rheumatoid arthritis correlated with the infiltration of inflammatory cells in synovial membrane
Tomoko Matsumoto et al.
RHEUMATOLOGY INTERNATIONAL (2006)
Interleukin-6: discovery of a pleiotropic cytokine
Tadamitsu Kishimoto
ARTHRITIS RESEARCH & THERAPY (2006)
Interleukin-6 and chronic inflammation
Cem Gabay
ARTHRITIS RESEARCH & THERAPY (2006)
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition
MC Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Anti-interleukin 6 receptor antibody treatment in rheumatic disease
N Nishimoto et al.
ANNALS OF THE RHEUMATIC DISEASES (2000)
Share Paper
